SOLVENT EVAPORATION METHOD: APROMISING SOLID DISPERSIONMETHOD USING BETACYCLODEXTRIN POLYMER FORENHANCING SOLUBILITY OFPOORLY SOLUBLE DRUGFEBUXOSTAT

Abstract

Febuxostat is nonpurine xanthine oxidase inhibitor used in treatment of hyperuricemia and gout. Due to its poor solubility, it has less bioavailability. Hence this problem is solved by formulating a solid dispersion using beta cyclodextrin (β-CD) polymer by solvent evaporation method. Beta cyclodextrin (β CD) was used in different drug: carrier ratios (1:2, 1:4, 1:6, 1:8, and 1:10). SE1, SE2, SE3, SE4,SE5 respectively. The effect of these polymers at different ratios on aqueous solubility was studied. Solid dispersion was evaluated for physical appearance, percentage yield, drug content, saturation solubility studies and dissolution studies, etc. Result of saturation solubility studies revealed increase in solubility of the solid dispersions compared to the pure drug. Invitro release profiles of all solid dispersion were evaluated and studied against pure febuxostat drug. Solid dispersion SE5, having drug:β CD(1:10 ratio) showed a higher dissolution rate.The powder X-ray diffraction study and Scanning electron microscopy (SEM) studies exhibited conversion of crystalline drug to an amorphous form of solid dispersion.The present study demonstrated that formulation of solid dispersion using β CD method is a highly the best technique for solubility enhancement of febuxostat drug.